Medicare Rx Final Regs Retain CMS Right To Plans’ Drug Price Information
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency releases final rules implementing Title I and II of the Medicare Modernization Act. CMS’ authority to evaluate data on drug prices negotiated by Medicare prescription drug plans does not violate the “non-interference” provision of MMA, reg states. Drug price reviews will be “rare,” CMS says.